Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 76, Issue 3, 2005, Pages 320-324

  Connelly, P J ^a   Prentice, N P ^a   Fowler, K G ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b PERTH ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CHOLINESTERASE INHIBITION; CLINICAL OBSERVATION; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DAILY LIFE ACTIVITY; DIAGNOSTIC VALUE; DIGIT SYMBOL SUBSTITUTION TEST; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; OUTPATIENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RURAL AREA; SOCIAL BEHAVIOR; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 14544280149     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.043539     Document Type: Article

References (43)

1. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease-results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-44.
2. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of Rivastigmine in patients with Alzheimer's Disease: international randomised controlled trial. BMJ 1999;318:633-40.
3. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269-76.
4. Lilienfeld S, Parys W. Galantamine: additional benefits to patients with Alzheimer's Disease. Dement Geriatr Cogn Disord 2000;11(suppl 1):19-27.
5. Farlow MR, Hake A, Messina J, et al. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001;58:417-22.
6. Evans M, Ellis A, Watson D, et al. Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil. Int J Geriatr Psychiatry 2000;15:50-3.
7. Farlow MR, Schneider LS. Rivastigmine and response to treatment in different subgroups of patients with Alzheimer's Disease. NeurobiolAging 1998;(suppl 4S):1264.
8. Kumar V, Anand R, Messina J, et al. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000;7:159-69.
9. Poirier J, Delisle M-C, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's Disease. Proc Natl Acad Sci USA 1995;92:12260-4.
10. Aerssens J, Raemaekers P, Lilienfield S, et al. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001;12:69-77.
11. Lucotte G, Oddoze C, Michel B-F. Apolipoprotein E genotype allele epsilon4 and response to tacrine in Alzheimer's disease. Alzheimer's Res 1996;2:101-2.
12. Riekkinen P Jr, Soininen H, Helkala EL, et al. Hippocampal atrophy, acute THA treatment and memory in Alzheimer's disease. Neuroreport 1995;6:1297-300.
13. Riekkinen P Riekkinen Jr M, Soininen H, et al. Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease. Neuroreport 1997;8:1845-9.
14. Tanaka Y, Hanyu H, Sakurai H, et al. Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer's disease patients. Dement Geriatr Cogn Disord 2003;16:119-25.
15. Folstein MF, Folstein SE, McHugh PA. Mini Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
16. Sahakian BJ, Owen AM, Morant NJ, et al. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology 1993;110:395-401.
17. Alhainen K, Helkala EL, Riekkinen P. Psychometric discrimination of tetrahydroaminoacridine responders in Alzheimer patients. Dementia 1993;4:54-8.
18. Almkvist O, Jelic V, Amberla K, et al. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement Geriatr Cogn Disord 2001;12:22-30.
19. Knott V, Mohr E, Mahoney C, et al. Pharmaco-EEG test dose response predicts cholinesterase inhibitor treatment outcome in Alzheimer's Disease. Methods Find Exp Clin Pharmacol 2000;22:115-22.
20. Adler G, Brassen S, Chwalek K, et al. Prediction of treatment response to rivastigmine in Alzheimer's dementia. J Neurol Neurosurg Psychiatry 2004;75:292-4.
21. McKhann G, Drachman D, Falstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Task Force in Alzheimer's disease. Neurology 1984;34:939-44.
22. Rosen WG, Terry RD, Fuld PA, et al. Pathological verification of ischaemic score in differentiation of dementias. Ann Neurol 1980;7:486-8.
23. Tarvonen-Schröeder S, Röyttä M, Räihä I, et al. Clinical features of leukoaraiosis. J Neurol Neurosurg Psychiatr 1996;60:431-6.
24. Villardita C, Grioli S, Lomeo C, et al. Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree. Neuropsychobiology 1992;25:24-8.
25. Gupta SR, Naheedy MH, Young JC, et al. Periventricular white matter changes and dementia. Clinical, neuropsychological, radiological, and pathological correlation. Arch Neurol 1988;45:637-41.
26. Almkvist O, Wahlund LO, Lundman G, et al. White matter hyperintensity and neuropsychological functions in dementia and healthy ageing. Arch Neurol 1992;49:626-32.
27. McDonald C. Clinical heterogeneity in senile dementia. Br J Psychiatry 1969;115:267-71.
28. Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York: The Psychological Corporation, 1981.
29. Luria AR. Higher cortical functions in man. London: Tavistock, 1966.
30. Spiegel R, Brunner C, Ermini-Funfschilling D, et al. A new behavioural assessment scale for geriatric out- and in-patients: the NOSGER (Nurses Observation Scale for Geriatric Patients). J Am Geriatr Soc 1991;39:339-47.
31. Jobst KA, Smith AD, Szatmari M, et al. Detection in life of confirmed Alzheimer's Disease using a simple measurement of medical temporal lobe atrophy by compacted tomography. Lancet 1992;340:1183-8.
32. Iverson GL. Interpretation of Mini-Mental State Examination scores in community-dwelling elderly and geriatric neuro-psychiatry patients. Int J Geriatr Psychiatry 1998;13:661-6.
33. Cohen J. Statistical power analysis for the behavioural sciences, 2nd ed. Hillsdale, New Jersey: Lawrence Erlbaum Associates, 1988.
34. Han L, Cole M, Bellavance F, et al. Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis. Int Psychogeriatr 2000;12:231-47.
35. Raskind MA, Peskind MD, Wessel T, et al. Galantomine in AD: A six month randomized placebo controlled trial with a six month extension. Neurology 2000;54:2261-8.
36. Winblad B, Engedal K, Soininen H, et al. A one year randomized placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95.
37. Salthouse TA. What do adult age differences in the Digit Symbol Substitution Test reflect? J Gerontol 1992;47:121-128.
38. Muir JL, Everitt BJ, Robbins TW. Reversal of visual attentional dysfunction following lesions of the basal forebrain by physostigmine but not by the 5HT3 receptor antagonist ondansetron. Psychopharmacology 1995;118:82-92.
39. Oksengaard AR, Haakonsen M, Dullerud R, et al. Accuracy of CT scan measurements of the medial temporal lobe in routine dementia diagnostics. Int J Geriatr Psychiatry 2003;18:308-12.
40. Luce A, McKeith I, Swann A, et al. How do memory clinics compare with traditional old age psychiatry services. Int J Geriatr Psychiatry 2001;16:837-45.
41. Holmes C, Lovestone S. Long-term cognitive and functional decline in late-onset Alzheimer's disease: therapeutic implications. Age Ageing 2003;32:200-4.
42. Lopez OL, Becker JT, Jungreis CA, et al. Computed tomography but not magnetic resonance imaging identified periventricular white-matter lesions predict symptomatic cerebrovascular disease in probable Alzheimer's disease. Arch Neurol 1995;52:659-64.
43. Matthews HP, Korbey J, Wilkinson DG, et al. Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic. Int J Geriatr Psychiatry 2000;15:713-20.